{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:11:41Z","timestamp":1791465101870,"version":"4.3.4"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Infect Dis Rep"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s11908-010-0129-9","type":"journal-article","created":{"date-parts":[[2010,8,8]],"date-time":"2010-08-08T20:28:05Z","timestamp":1281299285000},"page":"423-429","source":"Crossref","is-referenced-by-count":130,"title":["Recent Advances in the Treatment of Mucormycosis"],"prefix":"10.1007","volume":"12","author":[{"given":"Brad","family":"Spellberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf S.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,8,10]]},"reference":[{"key":"129_CR1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.mycres.2007.03.004","volume":"111","author":"DS Hibbett","year":"2007","unstructured":"Hibbett DS, Binder M, Bischoff JF, et al.: A higher-level phylogenetic classification of the fungi. Mycol Res 2007, 111:509\u2013547.","journal-title":"Mycol Res"},{"key":"129_CR2","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","volume":"41","author":"MM Roden","year":"2005","unstructured":"Roden MM, Zaoutis TE, Buchanan WL, et al.: Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41:634\u2013653.","journal-title":"Clin Infect Dis"},{"key":"129_CR3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1128\/CMR.18.3.556-569.2005","volume":"18","author":"B Spellberg","year":"2005","unstructured":"Spellberg B, Edwards J Jr, Ibrahim A: Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005, 18:556\u2013569.","journal-title":"Clin Microbiol Rev"},{"key":"129_CR4","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/428780","volume":"191","author":"DP Kontoyiannis","year":"2005","unstructured":"Kontoyiannis DP, Lionakis MS, Lewis RE, et al.: Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191:1350\u20131360.","journal-title":"J Infect Dis"},{"key":"129_CR5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/313803","volume":"30","author":"DP Kontoyiannis","year":"2000","unstructured":"Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV: Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000, 30:851\u2013856.","journal-title":"Clin Infect Dis"},{"key":"129_CR6","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","volume":"34","author":"KA Marr","year":"2002","unstructured":"Marr KA, Carter RA, Crippa F, et al.: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34:909\u2013917.","journal-title":"Clin Infect Dis"},{"key":"129_CR7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/13693780903059477","volume":"48","author":"V Saegeman","year":"2010","unstructured":"Saegeman V, Maertens J, Ectors N, et al.: Epidemiology of mucormycosis: review of 18 cases in a tertiary care hospital. Med Mycol 2010, 48:245\u2013254.","journal-title":"Med Mycol"},{"key":"129_CR8","doi-asserted-by":"crossref","unstructured":"Ambrosioni J, Bouchuiguir-Wafa K, Garbino J: Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors. Int J Infect Dis 2010 (Epub ahead of print).","DOI":"10.1016\/j.ijid.2009.11.024"},{"key":"129_CR9","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1080\/10428190310001653691","volume":"45","author":"B Gleissner","year":"2004","unstructured":"Gleissner B, Schilling A, Anagnostopolous I, et al.: Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma 2004, 45:1351\u20131360.","journal-title":"Leuk Lymphoma"},{"key":"129_CR10","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3201\/eid1509.090334","volume":"15","author":"D Bitar","year":"2009","unstructured":"Bitar D, Van Cauteren D, Lanternier F, et al.: Increasing incidence of zygomycosis (mucormycosis), France, 1997\u20132006. Emerg Infect Dis 2009, 15:1395\u20131401.","journal-title":"Emerg Infect Dis"},{"key":"129_CR11","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1128\/CMR.13.2.236","volume":"13","author":"JA Ribes","year":"2000","unstructured":"Ribes JA, Vanover-Sams CL, Baker DJ: Zygomycetes in human disease. Clin Microbiol Rev 2000, 13:236\u2013301.","journal-title":"Clin Microbiol Rev"},{"key":"129_CR12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","volume":"48","author":"D Neofytos","year":"2009","unstructured":"Neofytos D, Horn D, Anaissie E, et al.: Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009, 48:265\u2013273.","journal-title":"Clin Infect Dis"},{"key":"129_CR13","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jac\/dkp430","volume":"65","author":"MJ Ruping","year":"2010","unstructured":"Ruping MJ, Heinz WJ, Kindo AJ, et al.: Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010, 65:296\u2013302.","journal-title":"J Antimicrob Chemother"},{"key":"129_CR14","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1111\/j.1600-6143.2009.02754.x","volume":"9","author":"HY Sun","year":"2009","unstructured":"Sun HY, Aguado JM, Bonatti H, et al.: Pulmonary zygomycosis in solid organ transplant recipients in the current era. Am J Transplant 2009, 9:2166\u20132171.","journal-title":"Am J Transplant"},{"key":"129_CR15","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Chamilos G, Lewis RE, Kontoyiannis DP: Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008, 47:503\u2013509. This article describes a very compelling study precisely defining the necessary timing of initiation of therapy for mucormycosis to maximize outcomes in the cancer setting.","DOI":"10.1086\/590004"},{"key":"129_CR16","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1128\/JCM.02246-07","volume":"46","author":"A Francesconi","year":"2008","unstructured":"Francesconi A, Kasai M, Harrington SM, et al.: Automated and manual methods of DNA extraction for Aspergillus fumigatus and Rhizopus oryzae analyzed by quantitative real-time PCR. J Clin Microbiol 2008, 46:1978\u20131984.","journal-title":"J Clin Microbiol"},{"key":"129_CR17","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1128\/JCM.02331-07","volume":"46","author":"DJ Hata","year":"2008","unstructured":"Hata DJ, Buckwalter SP, Pritt BS, et al.: Real-time PCR method for detection of zygomycetes. J Clin Microbiol 2008, 46:2353\u20132358.","journal-title":"J Clin Microbiol"},{"key":"129_CR18","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1128\/JCM.00917-08","volume":"46","author":"M Kasai","year":"2008","unstructured":"Kasai M, Harrington SM, Francesconi A, et al.: Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. J Clin Microbiol 2008, 46:3690\u20133702.","journal-title":"J Clin Microbiol"},{"key":"129_CR19","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1128\/JCM.02319-09","volume":"48","author":"E Dannaoui","year":"2010","unstructured":"Dannaoui E, Schwarz P, Slany M, et al.: Molecular detection and identification of zygomycetes species from paraffin-embedded tissues in a murine model of disseminated zygomycosis: a collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) evaluation. J Clin Microbiol 2010, 48:2043\u20132046.","journal-title":"J Clin Microbiol"},{"key":"129_CR20","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Reed C, Bryant R, Ibrahim AS, et al.: Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008, 47:364\u2013371. This retrospective study describes superior outcomes in patients with mucormycosis treated with combination polyene-echinocandin therapy.","DOI":"10.1086\/589857"},{"key":"129_CR21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1086\/430710","volume":"41","author":"G Chamilos","year":"2005","unstructured":"Chamilos G, Marom EM, Lewis RE, et al.: Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005, 41:60\u201366.","journal-title":"Clin Infect Dis"},{"key":"129_CR22","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI116419","volume":"91","author":"JR Boelaert","year":"1993","unstructured":"Boelaert JR, de Locht M, Van Cutsem J, et al.: Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993, 91:1979\u20131986.","journal-title":"J Clin Invest"},{"key":"129_CR23","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.1989.301","volume":"36","author":"J Cutsem Van","year":"1989","unstructured":"Van Cutsem J, Boelaert JR: Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis). Kidney Int 1989, 36:1061\u20131068.","journal-title":"Kidney Int"},{"key":"129_CR24","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Ibrahim AS, Gebermariam T, Fu Y, et al.: The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007, 117:2649\u20132657. This seminal study defines the potential for iron chelation to serve as synergistic, adjunctive therapy for mucormycosis.","DOI":"10.1172\/JCI32338"},{"key":"129_CR25","first-page":"231","volume":"51","author":"S Nithyanandam","year":"2003","unstructured":"Nithyanandam S, Jacob MS, Battu RR, et al.: Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian J Ophthalmol 2003, 51:231\u2013236.","journal-title":"Indian J Ophthalmol"},{"key":"129_CR26","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/00005537-199707000-00004","volume":"107","author":"KL Peterson","year":"1997","unstructured":"Peterson KL, Wang M, Canalis RF, Abemayor E: Rhinocerebral mucormycosis: evolution of the disease and treatment options. Laryngoscope 1997, 107:855\u2013862.","journal-title":"Laryngoscope"},{"key":"129_CR27","first-page":"266","volume":"36","author":"BS Khor","year":"2003","unstructured":"Khor BS, Lee MH, Leu HS, Liu JW: Rhinocerebral mucormycosis in Taiwan. J Microbiol Immunol Infect 2003, 36:266\u2013269.","journal-title":"J Microbiol Immunol Infect"},{"key":"129_CR28","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10096-003-1035-y","volume":"22","author":"G Petrikkos","year":"2003","unstructured":"Petrikkos G, Skiada A, Sambatakou H, et al.: Mucormycosis: ten-year experience at a tertiary-care center in Greece. Eur J Clin Microbiol Infect Dis 2003, 22:753\u2013756.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"129_CR29","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/0003-4975(94)90243-7","volume":"57","author":"M Tedder","year":"1994","unstructured":"Tedder M, Spratt JA, Anstadt MP, et al.: Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994, 57:1044\u20131050.","journal-title":"Ann Thorac Surg"},{"key":"129_CR30","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/00365540410021081a","volume":"36","author":"J Pavie","year":"2004","unstructured":"Pavie J, Lafaurie M, Lacroix C, et al.: Successful treatment of pulmonary mucormycosis in an allogenic bone-marrow transplant recipient with combined medical and surgical therapy. Scand J Infect Dis 2004, 36:767\u2013769.","journal-title":"Scand J Infect Dis"},{"key":"129_CR31","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0003-4975(03)01406-1","volume":"78","author":"VJ Reid","year":"2004","unstructured":"Reid VJ, Solnik DL, Daskalakis T, Sheka KP: Management of bronchovascular mucormycosis in a diabetic: a surgical success. Ann Thorac Surg 2004, 78:1449\u20131451.","journal-title":"Ann Thorac Surg"},{"key":"129_CR32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11748-003-0055-y","volume":"51","author":"K Asai","year":"2003","unstructured":"Asai K, Suzuki K, Takahashi T, et al.: Pulmonary resection with chest wall removal and reconstruction for invasive pulmonary mucormycosis during antileukemia chemotherapy. Jpn J Thorac Cardiovasc Surg 2003, 51:163\u2013166.","journal-title":"Jpn J Thorac Cardiovasc Surg"},{"key":"129_CR33","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/j.tripleo.2009.11.012","volume":"109","author":"NE McDermott","year":"2010","unstructured":"McDermott NE, Barrett J, Hipp J, et al.: Successful treatment of periodontal mucormycosis: report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010, 109:e64\u2013e69.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"129_CR34","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","volume":"26","author":"TJ Walsh","year":"1998","unstructured":"Walsh TJ, Hiemenz JW, Seibel NL, et al.: Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998, 26:1383\u20131396.","journal-title":"Clin Infect Dis"},{"key":"129_CR35","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1179\/joc.2009.21.3.322","volume":"21","author":"L Pagano","year":"2009","unstructured":"Pagano L, Valentini CG, Posteraro B, et al.: Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology). J Chemother 2009, 21:322\u2013329.","journal-title":"J Chemother"},{"key":"129_CR36","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1086\/605445","volume":"200","author":"N Singh","year":"2009","unstructured":"Singh N, Aguado JM, Bonatti H, et al.: Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009, 200:1002\u20131011.","journal-title":"J Infect Dis"},{"key":"129_CR37","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/315643","volume":"182","author":"AH Groll","year":"2000","unstructured":"Groll AH, Giri N, Petraitis V, et al.: Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000, 182:274\u2013282.","journal-title":"J Infect Dis"},{"key":"129_CR38","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1128\/AAC.01488-07","volume":"52","author":"AS Ibrahim","year":"2008","unstructured":"Ibrahim AS, Gebremariam T, Husseiny MI, et al.: Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother 2008, 52:1573\u20131576.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR39","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1128\/AAC.01449-06","volume":"51","author":"RE Lewis","year":"2007","unstructured":"Lewis RE, Liao G, Hou J, et al.: Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2007, 51:1253\u20131258.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR40","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","volume":"44","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Bresnik M, et al.: Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007, 44:1289\u20131297.","journal-title":"Clin Infect Dis"},{"key":"129_CR41","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","volume":"45","author":"TJ Walsh","year":"2001","unstructured":"Walsh TJ, Goodman JL, Pappas P, et al.: Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001, 45:3487\u20133496.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR42","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/AAC.46.5.1581-1582.2002","volume":"46","author":"QN Sun","year":"2002","unstructured":"Sun QN, Fothergill AW, McCarthy DI, et al.: In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002, 46:1581\u20131582.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR43","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bmt.1705614","volume":"39","author":"SM Trifilio","year":"2007","unstructured":"Trifilio SM, Bennett CL, Yarnold PR, et al.: Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007, 39:425\u2013429.","journal-title":"Bone Marrow Transplant"},{"key":"129_CR44","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1056\/NEJM200402263500923","volume":"350","author":"FM Marty","year":"2004","unstructured":"Marty FM, Cosimi LA, Baden LR: Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004, 350:950\u2013952.","journal-title":"N Engl J Med"},{"key":"129_CR45","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1086\/422729","volume":"39","author":"CA Kauffman","year":"2004","unstructured":"Kauffman CA: Zygomycosis: reemergence of an old pathogen. Clin Infect Dis 2004, 39:588\u2013590.","journal-title":"Clin Infect Dis"},{"key":"129_CR46","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1086\/423274","volume":"39","author":"A Imhof","year":"2004","unstructured":"Imhof A, Balajee SA, Fredricks DN, et al.: Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004, 39:743\u2013746.","journal-title":"Clin Infect Dis"},{"key":"129_CR47","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1469-0691.2004.00945.x","volume":"10","author":"L Ide","year":"2004","unstructured":"Ide L, Buysschaert I, Demuynck H, et al.: Zygomycosis in neutropenic patients with past Aspergillus infection: a role for posaconazole? Clin Microbiol Infect 2004, 10:862\u2013863.","journal-title":"Clin Microbiol Infect"},{"key":"129_CR48","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1086\/427752","volume":"40","author":"S Vigouroux","year":"2005","unstructured":"Vigouroux S, Morin O, Moreau P, et al.: Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 2005, 40:e35\u2013e37.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"129_CR49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1439-0507.2002.tb04542.x","volume":"45","author":"V Rickerts","year":"2002","unstructured":"Rickerts V, B\u00f6hme A, Just-N\u00fcbling G: Risk factor for invasive zygomycosis in patients with hematologic malignancies [in German]. Mycoses 2002, 45(Suppl 1):27\u201330.","journal-title":"Mycoses"},{"key":"129_CR50","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1128\/AAC.47.11.3647-3650.2003","volume":"47","author":"E Dannaoui","year":"2003","unstructured":"Dannaoui E, Meis JF, Loebenberg D, Verweij PE: Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 2003, 47:3647\u20133650.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR51","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/dkg020","volume":"51","author":"E Dannaoui","year":"2003","unstructured":"Dannaoui E, Meletiadis J, Mouton JW, et al.: In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003, 51:45\u201352.","journal-title":"J Antimicrob Chemother"},{"key":"129_CR52","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000238681","volume":"35","author":"J Cutsem Van","year":"1989","unstructured":"Van Cutsem J, Van Gerven F, Fransen J, Janssen PA: Treatment of experimental zygomycosis in guinea pigs with azoles and with amphotericin B. Chemotherapy 1989, 35:267\u2013272.","journal-title":"Chemotherapy"},{"key":"129_CR53","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/AAC.46.4.1032-1037.2002","volume":"46","author":"MA Pfaller","year":"2002","unstructured":"Pfaller MA, Messer SA, Hollis RJ, Jones RN: Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002, 46:1032\u20131037.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR54","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1128\/AAC.00452-07","volume":"51","author":"NG Almyroudis","year":"2007","unstructured":"Almyroudis NG, Sutton DA, Fothergill AW, et al.: In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007, 51:2587\u20132590.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR55","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1128\/AAC.00662-08","volume":"52","author":"C Lass-Fl\u00f6rl","year":"2008","unstructured":"Lass-Fl\u00f6rl C, Mayr A, Perkhofer S, et al.: Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2008, 52:3637\u20133641.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR56","first-page":"1","volume":"12","author":"S Arikan","year":"2008","unstructured":"Arikan S, Sancak B, Alp S, et al.: Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med Mycol 2008, 12:1\u20137.","journal-title":"Med Mycol"},{"key":"129_CR57","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1128\/AAC.50.2.658-666.2006","volume":"50","author":"AJ Ullmann","year":"2006","unstructured":"Ullmann AJ, Cornely OA, Burchardt A, et al.: Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006, 50:658\u2013666.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR58","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1128\/AAC.00454-06","volume":"51","author":"G Krishna","year":"2007","unstructured":"Krishna G, Sansone-Parsons A, Martinho M, et al.: Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007, 51:812\u2013818.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR59","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1592\/phco.27.12.1627","volume":"27","author":"G Krishna","year":"2007","unstructured":"Krishna G, Martinho M, Chandrasekar P, et al.: Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007, 27:1627\u20131636.","journal-title":"Pharmacotherapy"},{"key":"129_CR60","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1128\/AAC.46.7.2310-2312.2002","volume":"46","author":"QN Sun","year":"2002","unstructured":"Sun QN, Najvar LK, Bocanegra R, et al.: In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 2002, 46:2310\u20132312.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR61","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1128\/AAC.00628-08","volume":"52","author":"MM Rodriguez","year":"2008","unstructured":"Rodriguez MM, Serena C, Marine M, et al.: Posaconazole combined with amphotericin B, an effective therapy for a murine-disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother 2008, 52:3786\u20133788.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR62","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1128\/AAC.01124-08","volume":"53","author":"AS Ibrahim","year":"2009","unstructured":"Ibrahim AS, Gebremariam T, Schwartz JA, et al.: Posaconazole mono- or combination therapy for murine mucormycosis. Antimicrob Agents Chemother 2009, 53:772\u2013775.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR63","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.bbmt.2009.04.007","volume":"15","author":"LJ Lekakis","year":"2009","unstructured":"Lekakis LJ, Lawson A, Prante J, et al.: Fatal rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: two cases and review of the literature. Biol Blood Marrow Transplant 2009, 15:991\u2013995.","journal-title":"Biol Blood Marrow Transplant"},{"key":"129_CR64","doi-asserted-by":"crossref","unstructured":"Mousset S, Bug G, Heinz WJ, et al.: Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation. Transpl Infect Dis 2009 (Epub ahead of print).","DOI":"10.1111\/j.1399-3062.2009.00479.x"},{"key":"129_CR65","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bmt.2008.199","volume":"42","author":"F Schlemmer","year":"2008","unstructured":"Schlemmer F, Lagrange-Xelot M, Lacroix C, et al.: Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplant 2008, 42:551\u2013552.","journal-title":"Bone Marrow Transplant"},{"key":"129_CR66","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","volume":"42","author":"JA Burik van","year":"2006","unstructured":"van Burik JA, Hare RS, Solomon HF, et al.: Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006, 42:e61\u2013e65.","journal-title":"Clin Infect Dis"},{"key":"129_CR67","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","volume":"50","author":"RN Greenberg","year":"2006","unstructured":"Greenberg RN, Mullane K, van Burik JA, et al.: Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006, 50:126\u2013133.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR68","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1128\/AAC.49.2.721-727.2005","volume":"49","author":"AS Ibrahim","year":"2005","unstructured":"Ibrahim AS, Bowman JC, Avanessian V, et al.: Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005, 49:721\u2013727.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR69","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/AAC.49.2.830-832.2005","volume":"49","author":"B Spellberg","year":"2005","unstructured":"Spellberg B, Fu Y, Edwards JE Jr, Ibrahim AS: Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005, 49:830\u2013832.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR70","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1128\/AAC.01458-07","volume":"52","author":"AS Ibrahim","year":"2008","unstructured":"Ibrahim AS, Gebremariam T, Fu Y, et al.: Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008, 52:1556\u20131558.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR71","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/13693780802326001","volume":"47","author":"AS Ibrahim","year":"2009","unstructured":"Ibrahim AS, Edwards JE Jr, Bryant R, Spellberg B: Economic burden of mucormycosis in the United States: can a vaccine be cost-effective? Med Mycol 2009, 47:592\u2013600.","journal-title":"Med Mycol"},{"key":"129_CR72","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/ki.1994.89","volume":"45","author":"JR Boelaert","year":"1994","unstructured":"Boelaert JR, Van Cutsem J, de Locht M, et al.: Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int 1994, 45:667\u2013671.","journal-title":"Kidney Int"},{"key":"129_CR73","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/0006-2952(94)90314-X","volume":"47","author":"M Locht de","year":"1994","unstructured":"de Locht M, Boelaert JR, Schneider YJ: Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol 1994, 47:1843\u20131850.","journal-title":"Biochem Pharmacol"},{"key":"129_CR74","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/jac\/dkl350","volume":"58","author":"AS Ibrahim","year":"2006","unstructured":"Ibrahim AS, Edwards JE Jr, Fu Y, Spellberg B: Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 2006, 58:1070\u20131073.","journal-title":"J Antimicrob Chemother"},{"key":"129_CR75","doi-asserted-by":"crossref","unstructured":"Ibrahim AS, Gebremariam T, Lin L, et al.: The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol 2010 (Epub ahead of print).","DOI":"10.1111\/j.1365-2958.2010.07234.x"},{"key":"129_CR76","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Liu M, Spellberg B, Phan QT, et al.: The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest 2010, 120:1914\u20131924. This study elucidates a primary mechanism by which iron regulates host susceptibility to mucormycosis.","DOI":"10.1172\/JCI42164"},{"key":"129_CR77","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.beha.2004.09.002","volume":"18","author":"MD Cappellini","year":"2005","unstructured":"Cappellini MD: Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract Res Clin Haematol 2005, 18:289\u2013298.","journal-title":"Best Pract Res Clin Haematol"},{"key":"129_CR78","first-page":"873","volume":"91","author":"A Piga","year":"2006","unstructured":"Piga A, Galanello R, Forni GL, et al.: Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006, 91:873\u2013880.","journal-title":"Haematologica"},{"key":"129_CR79","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12185-008-0115-2","volume":"88","author":"K Miyazawa","year":"2008","unstructured":"Miyazawa K, Ohyashiki K, Urabe A, et al.: A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a phase I study in Japan. Int J Hematol 2008, 88:73\u201381.","journal-title":"Int J Hematol"},{"key":"129_CR80","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1128\/AAC.01065-06","volume":"50","author":"C Reed","year":"2006","unstructured":"Reed C, Ibrahim A, Edwards JE Jr, et al.: Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006, 50:3968\u20133969.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR81","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1128\/AAC.00361-09","volume":"53","author":"B Spellberg","year":"2009","unstructured":"Spellberg B, Andes D, Perez M, et al.: Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother 2009, 53:3122\u20133125.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR82","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ajh.21119","volume":"83","author":"E Vichinsky","year":"2007","unstructured":"Vichinsky E: Clinical application of deferasirox: practical patient management. Am J Hematol 2007, 83:398\u2013402.","journal-title":"Am J Hematol"},{"key":"129_CR83","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-4615-0593-8_10","volume":"509","author":"H Nick","year":"2002","unstructured":"Nick H, Wong A, Acklin P, et al.: ICL670A: preclinical profile. Adv Exp Med Biol 2002, 509:185\u2013203.","journal-title":"Adv Exp Med Biol"},{"key":"129_CR84","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","volume":"107","author":"MD Cappellini","year":"2006","unstructured":"Cappellini MD, Cohen A, Piga A, et al.: A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006, 107:3455\u20133462.","journal-title":"Blood"},{"key":"129_CR85","unstructured":"US Food and Drug Administration: Important information about Exjade (deferasirox) tablets for oral suspension (Novartis, 2007). Available at http:\/\/www.fda.gov\/downloads\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/UCM154395.pdf . Accessed June 2010."},{"key":"129_CR86","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1128\/AAC.00956-09","volume":"54","author":"R Ben-Ami","year":"2010","unstructured":"Ben-Ami R, Lewis RE, Tarrand J, et al.: Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection. Antimicrob Agents Chemother 2010, 54:484\u2013490.","journal-title":"Antimicrob Agents Chemother"},{"key":"129_CR87","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1086\/428503","volume":"191","author":"C Gil-Lamaignere","year":"2005","unstructured":"Gil-Lamaignere C, Simitsopoulou M, Roilides E, et al.: Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 2005, 191:1180\u20131187.","journal-title":"J Infect Dis"},{"key":"129_CR88","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/01.inf.0000134314.65398.bf","volume":"23","author":"MJ Abzug","year":"2004","unstructured":"Abzug MJ, Walsh TJ: Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J 2004, 23:769\u2013773.","journal-title":"Pediatr Infect Dis J"},{"key":"129_CR89","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/clinids\/24.2.192","volume":"24","author":"CE Gonzalez","year":"1997","unstructured":"Gonzalez CE, Couriel DR, Walsh TJ: Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis 1997, 24:192\u2013196.","journal-title":"Clin Infect Dis"},{"key":"129_CR90","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0923-2494(98)80771-2","volume":"149","author":"BJ Kullberg","year":"1998","unstructured":"Kullberg BJ, Anaissie EJ: Cytokines as therapy for opportunistic fungal infections. Res Immunol 1998, 149:478\u2013488; discussion 515.","journal-title":"Res Immunol"},{"key":"129_CR91","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00520-005-0910-8","volume":"14","author":"L Grigull","year":"2006","unstructured":"Grigull L, Beilken A, Schmid H, et al.: Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies. Support Care Cancer 2006, 14:783\u2013786.","journal-title":"Support Care Cancer"},{"key":"129_CR92","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1469-0691.2005.01170.x","volume":"11","author":"BV John","year":"2005","unstructured":"John BV, Chamilos G, Kontoyiannis DP: Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect 2005, 11:515\u2013517.","journal-title":"Clin Microbiol Infect"},{"key":"129_CR93","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1439-0507.2009.01708.x","volume":"53","author":"A Busca","year":"2010","unstructured":"Busca A, Marmont F, Locatelli F, et al.: Combined antifungal therapy, iron chelation and surgical resection as treatment of hepatic zygomycosis in a patient with haematological malignancy. Mycoses 2010, 53:275\u2013278.","journal-title":"Mycoses"},{"key":"129_CR94","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1128\/AAC.01026-09","volume":"53","author":"MM Rodriguez","year":"2009","unstructured":"Rodriguez MM, Pastor FJ, Calvo E, et al.: Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection. Antimicrob Agents Chemother 2009, 53:5022\u20135025.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Current Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s11908-010-0129-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T08:55:26Z","timestamp":1559379326000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11908-010-0129-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,10]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["129"],"URL":"https:\/\/doi.org\/10.1007\/s11908-010-0129-9","relation":{},"ISSN":["1523-3847","1534-3146"],"issn-type":[{"value":"1523-3847","type":"print"},{"value":"1534-3146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,10]]}}}